Unknown PHASE3 INTERVENTIONAL 2-arm NCT03856697

Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

A Randomized Controlled, Double-blind, Multicenter, Phase III Clinical Study to Compare Efficacy and Safety of Abivertinib Maleate Versus First-line Standard Therapy EGFR-TKI in Patients With Advanced NSCLC With Sensitive EGFR Mutation

Sponsor: Guangdong Provincial People's Hospital

Conditions Advanced Non-small Cell Lung Cancer

Interventions Abivertinib Maleate Capsules Gefitinib Tablets Placebo Abivertinib Maleate Capsules Placebo Gefitinib Tablets

Updated 5 times since 2019 Last updated: Feb 25, 2019 Started: Mar 31, 2019 Primary completion: Mar 31, 2022 Completion: Mar 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03856697, this PHASE3 trial focuses on Advanced Non-small Cell Lung Cancer and remains ongoing. Sponsored by Guangdong Provincial People's Hospital, it has been updated 5 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Apr 2024 — Jul 2024 [monthly]

Unknown Status PHASE3

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Apr 2024 [monthly]

Not Yet Recruiting PHASE3
Mar 2019 — Jan 2021 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Guangdong Provincial People's Hospital
Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Data source: Hangzhou ACEA Pharmaceutical Research Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China